Employers Have Variety of Approaches for High-Cost Drugs
As more high-cost drugs, including one-time gene therapies, come onto the market, employers are considering implementing a variety of contracting models to make sure their employees have access to these agents. Precision’s Jorge Font and Erin Lopata explore these innovative new approaches, as well as the challenges in executing them.
Precision Medicine Group Joins the Business Coalition for Equality Act
The Equality Act, currently moving through Congress, would make LGBTQ+ discrimination explicitly illegal. Precision Medicine Group believes that this Act is too important to leave its passage to chance. That is why we have joined a group of 446 leading American companies in signing the Business Coalition for the Equality Act. (more…)
On-Demand Webinar: Essential Strategies for Gene Therapy: From Assay Development to CDx Commercialization
Innovators developing gene therapies face a multitude of challenges, from the lab to the FDA. Yet a number of successful strategies are emerging that are mitigating the risks, reducing costs and smoothing out the road to approval. Listen to a panel of gene therapy experts with unique perspectives and real-world experiences share successful approaches in gene therapy development, CDx development and commercialization.
Gene Therapy for Rare Disorders Panel Summary
Recently, Precision ADVANCE’s Anshul Mangal moderated “Considerations for Early-Stage Gene Therapy Start-Ups: From Clinical Development to Manufacturing to Commercialization,” at the Gene Therapy for Rare Disorders virtual conference.
Precision ADVANCE Company Presentation: Meeting on the Med
At the Meeting on the Med 2021 Conference, CEO & Co-Founder of Precision Medicine Group Mark Clein gave an informative presentation highlighting Precision ADVANCE, the cell & gene therapy collective™, and how it aligns with our mission to help bring life-changing therapies to those that need them the most.